Opioid switch from low dose of oral oxycodone to transdermal fentanyl matrix patch for patients with stable thoracic malignancy-related pain

Table 5 Adverse events

	N	Day 1	Day 8	Day 15	p-value^a
Sleepiness	45				0.004
Mean ± SD		1.2 ± 0.7	0.9 ± 0.6	0.73 ± 0.8
Median (range)		1 (0 - 3)	1 (0 - 2)	1 (0 - 3)
vs. day 1^b			n.s.	<0.05
Nausea	49				0.87
Mean ± SD		0.4 ± 0.8	0.4 ± 0.7	0.3 ± 0.6
Median (range)		0 (0 - 3)	0 (0 - 3)	0 (0 - 2)
Vomit	49				0.66
Mean ± SD		0.1 ± 0.6	0.2 ± 0.6	0.1 ± 0.5
Median (range)		0 (0 - 3)	0 (0 - 3)	0 (0 - 2)
Constipation	48				0.08
Mean ± SD		0.5 ± 0.7	0.3 ± 0.5	0.3 ± 0.5
median (range)		0 (0 - 3)	0 (0 - 2)	0 (0 - 2)
Defecation number (/ day)	49				0.85
Mean ± SD		1.1 ± 1.0	1.0 ± 0.8	1.0 ± 0.7
Median (range)		1 (0 - 4)	1 (0 - 4)	1 (0 - 4)
Epworth Sleep Scale	49				0.96
Mean ± SD		6.3 ± 4.0	6.1 ± 4.2	6.0 ± 4.2
Median (range)		6 (0 - 16)	5 (0 - 18)	5 (0 - 19)

SD; standard deviation, n.s.; not significant (p > 0.05).
^aFriedman test.
^bPost-hoc nonparametric multiple comparison analysis was performed using Steel method after significant difference in assessment scores across multiple points was detected by Freidman test (p = 0.01).

ISSN: 1472-684X